Regeneron Pharmaceuticals Inc Regeneron (NASDAQ: REGN) And Sanofi’s Dupixent Accepted For Review By FDA Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) revealed on Thursday that FDA has awarded the authorization to Dupixent as an add-on cure for moderate-to-severe asthma.
Regeneron Pharmaceuticals Inc Regeneron (NASDAQ: REGN) To Deliver Antibody Drug To Czech Ahead Of EU Registration Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is preparing to deliver 12, 000 antibody treatment to the Czech Republic before the authorization of the EU.
